Technical Analysis for IMMU - Immunomedics, Inc.

Grade Last Price % Change Price Change
grade C 11.75 -2.08% -0.25
IMMU closed down 2.08 percent on Friday, November 17, 2017, on 80 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. It was able to find support at its 50 day moving average.
Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical IMMU trend table...

Date Alert Name Type % Chg
Nov 17 50 DMA Support Bullish 0.00%
Nov 17 NR7 Range Contraction 0.00%
Nov 17 Calm After Storm Range Contraction 0.00%
Nov 16 Crossed Above 50 DMA Bullish -2.08%
Nov 16 Calm After Storm Range Contraction -2.08%

Older signals for IMMU ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Basic chart:

Immunomedics, Inc., a biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune, and other serious diseases. Its products include epratuzumab, which is in two Phase III clinical trials for the treatment of lupus; Yttrium-90 labeled clivatuzumab tetraxetan, a therapeutic product candidate that completed a Phase Ib clinical trial for the treatment of pancreatic cancer; and Veltuzumab, a humanized anti-CD20 monoclonal antibody for the treatment of non-Hodgkin lymphoma (NHL). The company's products also comprise Milatuzumab, a transmembrane protein that is highly expressed in MM and other B-cell lymphomas and leukemias, and in certain solid tumors; Yttrium-90-Labeled Epratuzumab Tetraxetan, a radiolabeled CD22 antibody product candidate for patients with NHL; Labetuzumab, a proprietary humanized antibody, which is in Phase II clinical development stage, targets the carcinoembryonic antigen, CEACAM5; and hRS7, an internalizing humanized anti-epithelial glycoprotein-1 antibody. It also manufactures and commercializes LeukoScan, a diagnostic imaging system to determine the location and extent of infection/inflammation in bone in patients with suspected osteomyelitis, including patients with diabetic foot ulcers. The company has strategic partnerships and relationships with Nycomed GmbH and UCB, S.A.; and a collaboration agreement with Algeta ASA for the development of epratuzumab. Immunomedics, Inc. was founded in 1982 and is headquartered in Morris Plains, New Jersey.
Is IMMU a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 14.48
52 Week Low 3.01
Average Volume 2,863,797
200-Day Moving Average 8.4402
50-Day Moving Average 11.6185
20-Day Moving Average 10.9815
10-Day Moving Average 10.956
Average True Range 0.9859
ADX 14.0
+DI 26.07
-DI 20.85
Chandelier Exit (Long, 3 ATRs ) 9.8723
Chandelier Exit (Short, 3 ATRs ) 12.6777
Upper Bollinger Band 12.206
Lower Bollinger Band 9.757
Percent B (%b) 0.81
BandWidth 22.301143
MACD Line -0.0322
MACD Signal Line -0.1711
MACD Histogram 0.1389
Fundamentals Value
Market Cap 1.31 Billion
Num Shares 111 Million
EPS -1.47
Price-to-Earnings (P/E) Ratio -7.99
Price-to-Sales 396.34
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 12.55
Resistance 3 (R3) 12.56 12.31 12.41
Resistance 2 (R2) 12.31 12.11 12.30 12.37
Resistance 1 (R1) 12.03 11.98 11.91 12.02 12.32
Pivot Point 11.78 11.78 11.72 11.77 11.78
Support 1 (S1) 11.50 11.58 11.38 11.49 11.18
Support 2 (S2) 11.25 11.45 11.24 11.13
Support 3 (S3) 10.97 11.25 11.09
Support 4 (S4) 10.96